This webcast features: Claire Tardy, PhD, Research & Development Manager, Capsule Delivery Solutions, Lonza Pharma & Biotech![Lonza-11-12-19-ATE-300x198.png Lonza-11-12-19-ATE-300x198.png](https://eu-images.contentstack.com/v3/assets/blt0a48a1f3edca9eb0/blt2139625a291320ec/6572ed93594d70040a158475/Lonza-11-12-19-ATE-300x198.png?width=700&auto=webp&quality=80&disable=upscale)
Dry-powder inhalation (DPI) is a major drug delivery technology for the treatment of respiratory diseases and increasingly for systemic drug delivery. Providing a uniform dose in a portable, easy-to-use system, capsule-based DPI is a simple and cost-effective way to deliver medication via the pulmonary route.
Within dry-powder inhalation application fields, Lonza offers the Capsugel® Zephyr™ Dry-Powder Inhalation portfolio: high-quality capsule solutions based on different polymers, tailored to enable consistent and optimal release performance. Polymer science and engineering have opened a new era of functional development, which offers the potential for selecting the right capsule for different APIs and different inhalation devices associated with a wider range of services.
Building on a history of innovation in polymer science and capsule engineering, the Capsugel® brand, now part of Lonza, offers a suite of HPMC and other polymer capsules for the pharmaceutical world. In this webinar, learn more about the Capsugel® Zephyr™ Dry-Powder Inhalation capsule portfolio.
Watch the recorded webcast below.